QGEN.BRN Stock Chart & Stats
CHF50.36
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF50.36
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF50.36 - CHF50.36
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
CHF6.90B
Enterprise ValueCHF9.37K
Total Cash (Recent Filing)CHF646.29M
Total Debt (Recent Filing)CHF1.65B
Price to Earnings (P/E)21.9
BetaN/A
Next Earnings
Nov 10, 2026EPS Estimate
0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.89
Shares Outstanding206,074,750
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.61
Price to Sales (P/S)4.71
P/FCF Ratio21.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF35.19Price Target Upside-30.12% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)1.96
Revenue Forecast (FY)CHF1.73B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables/installed BaseQiagen’s core business model centers on consumables and instruments that create durable pull‑through demand. Installed platforms and repeat purchases support predictable, high‑frequency revenue streams, underpinning resilience in sales and margins across research and clinical workflows.
High And Sustainable MarginsThe company’s assay and reagent mix delivers high gross margins and healthy EBIT/EBITDA margins, reflecting differentiated products and favorable mix. Strong operating profitability provides structural capacity to fund R&D, commercialization, and shareholder returns even amid cyclical demand shifts.
Strong Cash Generation & Capital ReturnsConsistent operating cash generation and recent large repurchase plus a 40% dividend increase indicate durable free cash capacity and disciplined capital allocation. This supports sustained shareholder returns and optionality for reinvestment in product rollouts and automation placements.
Bears Say
QuantiFERON Revenue HeadwindA meaningful portion of prior QuantiFERON sales came from immigration testing; its decline removed roughly $35M and management moderated its 2026 target. Heavy reliance on one large product line makes top‑line durability vulnerable to policy, seasonal or competitive shifts in testing volumes.
Weaker FCF Conversion & Cash VolatilityAlthough operating cash is positive, free cash flow conversion lags (about 69% of net income) and has shown large swings. This structural variability can constrain reinvestment or capital return consistency during weaker earnings periods and increases sensitivity to working capital or inventory shifts.
Strategic/leadership UncertaintyA management transition and active strategic review introduce execution risk and can delay decisive capital allocation or product commercialization. Prolonged uncertainty may slow integration of launches, hamper long‑term strategy clarity, and increase execution risk across international rollout plans.
Qiagen News
QGEN.BRN FAQ
What was Qiagen NV’s price range in the past 12 months?
Qiagen NV lowest stock price was CHF50.36 and its highest was CHF50.36 in the past 12 months.
What is Qiagen NV’s market cap?
Qiagen NV’s market cap is CHF6.90B.
When is Qiagen NV’s upcoming earnings report date?
Qiagen NV’s upcoming earnings report date is Nov 10, 2026 which is in 93 days.
How were Qiagen NV’s earnings last quarter?
Qiagen NV released its earnings results on Aug 05, 2026. The company reported CHF0.501 earnings per share for the quarter, beating the consensus estimate of CHF0.483 by CHF0.018.
Is Qiagen NV overvalued?
According to Wall Street analysts Qiagen NV’s price is currently Overvalued.
Does Qiagen NV pay dividends?
Qiagen NV does not currently pay dividends.
What is Qiagen NV’s EPS estimate?
Qiagen NV’s EPS estimate is 0.5.
How many shares outstanding does Qiagen NV have?
Qiagen NV has 206,074,750 shares outstanding.
What happened to Qiagen NV’s price movement after its last earnings report?
Qiagen NV reported an EPS of CHF0.501 in its last earnings report, beating expectations of CHF0.483. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Qiagen NV?
Currently, no hedge funds are holding shares in CH:QGEN.BRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Qiagen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF35.19 (-30.12% Downside)
CHF35.19 (-30.12% Downside)
Blogger Sentiment
Bullish
CH:QGEN.BRN Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth CHF2.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 91%
Bearish news 9%
Bearish news 9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.65%
12-Months-Change
Fundamentals
Return on Equity
6.82%
Trailing 12-Months
Asset Growth
4.27%
Trailing 12-Months
Company Description
Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
QGEN.BRN Company Deck
QGEN.BRN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: management reported results above outlook for sales and adjusted EPS, strong cash generation, high profitability, and clear momentum in key growth pillars (Sample Technologies, QIAcuity, QDI) alongside active product launches and capital returns (40% dividend increase, $500M repurchase). Challenges include declines in QIAstat and PCR product groups, China and regional softness, a notable revenue loss from reduced immigration testing (~$35M) affecting QuantiFERON comparisons, modest margin and inventory pressures, and ongoing strategic/leadership transition that creates near-term uncertainty. On balance, the company emphasized confidence in a stronger second half of 2026 driven by new product rollouts and easing comparables.View all CH:QGEN.BRN earnings summariesQGEN.BRN Stock 12 Month Forecast
Average Price Target
CHF35.19
▼(-30.12% Downside)